Paper41375124
Design, Synthesis, Molecular Docking, and Anticancer Activity of Chalcone Derivatives as VEGFR-2 Inhibitors.
Yu M and 3 others. Molecules, 2025. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. Design, Synthesis, Molecular Docking, and Anticancer Activity of Chalcone Derivatives as VEGFR-2 Inhibitors. Papers, record 41375124. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41375124
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Design, Synthesis, Molecular Docking, and Anticancer Activity of Chalcone Derivatives as VEGFR-2 Inhibitors.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Vascular Endothelial Growth Factor Receptor-2 | Major topic |
| Antineoplastic Agents | Major topic |
| Drug Design | Major topic |
| Chalcones | Major topic |
| Protein Kinase Inhibitors | Major topic |
| Chalcone | Major topic |
| Molecular Docking Simulation | |
| Humans | |
| Cell Line, Tumor | |
| Apoptosis | |
| Structure-Activity Relationship | |
| Cell Proliferation | |
| Drug Screening Assays, Antitumor | |
| Molecular Structure | |
| Animals |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| BYKQ202417 | Bozhou University Research Initiation Program | PubMed | ||
| BYH2025020 | Bozhou University Enterprise Cooperation Project | PubMed | ||
| 2022XJXM057 | Bozhou University Teaching Reform Program | PubMed | ||
| 2024jsqygz135 | Anhui Province University Science and Engineering Teachers' Internship Program in Enterprises | PubMed |
Source PubMed
References47
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 39138146 | Therapeutic advances of targeting receptor tyrosine kinases in cancer. | Signal Transduct Target Ther | 2024 | https://conductscience.org/library/papers/39138146 | PubMed |
| 2 | 33076807 | Tumor Angiogenesis and VEGFR-2: Mechanism, Pathways and Current Biological Therapeutic Interventions. | Curr Drug Metab | 2021 | https://conductscience.org/library/papers/33076807 | PubMed |
| 3 | 20629091 | Targeted molecular therapy of head and neck squamous cell carcinoma with the tyrosine kinase inhibitor vandetanib in a mouse model. | Head Neck | 2011 | https://conductscience.org/library/papers/20629091 | PubMed |
| 4 | 12094254 | Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. | Leukemia | 2002 | https://conductscience.org/library/papers/12094254 | PubMed |
| 5 | 33670650 | Molecular Targeting of Epidermal Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor Receptor (VEGFR). | Molecules | 2021 | https://conductscience.org/library/papers/33670650 | PubMed |
| 6 | 35820328 | New fluorinated diarylureas linked to pyrrolo[2,3-d]pyrimidine scaffold as VEGFR-2 inhibitors: Molecular docking and biological evaluation. | Bioorg Chem | 2022 | https://conductscience.org/library/papers/35820328 | PubMed |
| 7 | 38969664 | A comprehensive review of computational cell cycle models in guiding cancer treatment strategies. | NPJ Syst Biol Appl | 2024 | https://conductscience.org/library/papers/38969664 | PubMed |
| 8 | 33536909 | Pharmacological Properties of Chalcones: A Review of Preclinical Including Molecular Mechanisms and Clinical Evidence. | Front Pharmacol | 2020 | https://conductscience.org/library/papers/33536909 | PubMed |
| 9 | 35799213 | Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy. | J Hematol Oncol | 2022 | https://conductscience.org/library/papers/35799213 | PubMed |
| 10 | 33171134 | Antioxidant and anti-inflammatory effects of hesperidin methyl chalcone in experimental ulcerative colitis. | Chem Biol Interact | 2021 | https://conductscience.org/library/papers/33171134 | PubMed |
| 11 | 36186578 | Urea-based anticancer agents. Exploring 100-years of research with an eye to the future. | Front Chem | 2022 | https://conductscience.org/library/papers/36186578 | PubMed |
| 12 | 36335233 | The use of machine learning modeling, virtual screening, molecular docking, and molecular dynamics simulations to identify potential VEGFR2 kinase inhibitors. | Sci Rep | 2022 | https://conductscience.org/library/papers/36335233 | PubMed |
| 13 | 34043477 | An updated patent review of VEGFR-2 inhibitors (2017-present). | Expert Opin Ther Pat | 2021 | https://conductscience.org/library/papers/34043477 | PubMed |
| 14 | 33476864 | Design and synthesis of methoxyphenyl- and coumarin-based chalcone derivatives as anti-inflammatory agents by inhibition of NO production and down-regulation of NF-κB in LPS-induced RAW264.7 macrophage cells. | Bioorg Chem | 2021 | https://conductscience.org/library/papers/33476864 | PubMed |
| 15 | 37338020 | Synthesis, reactions and application of chalcones: a systematic review. | Org Biomol Chem | 2023 | https://conductscience.org/library/papers/37338020 | PubMed |
| 16 | 38281295 | Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trial. | Gastric Cancer | 2024 | https://conductscience.org/library/papers/38281295 | PubMed |
| 17 | 36555234 | The VEGF/VEGFR Axis Revisited: Implications for Cancer Therapy. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36555234 | PubMed |
| 18 | 38370458 | New pyrazolylindolin-2-one based coumarin derivatives as anti-melanoma agents: design, synthesis, dual BRAFV600E/VEGFR-2 inhibition, and computational studies. | RSC Adv | 2024 | https://conductscience.org/library/papers/38370458 | PubMed |
| 19 | 35109719 | Angiogenesis and anti-leukaemia activity of novel indole derivatives as potent colchicine binding site inhibitors. | J Enzyme Inhib Med Chem | 2022 | https://conductscience.org/library/papers/35109719 | PubMed |
| 20 | 33972962 | Naturally occurring prenylated chalcones from plants: structural diversity, distribution, activities and biosynthesis. | Nat Prod Rep | 2021 | https://conductscience.org/library/papers/33972962 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42548118 | Recent Progress in Urea-Containing Compounds as Tyrosine Kinase Inhibitors. | Chem Biodivers | 2026 | https://conductscience.org/library/papers/42548118 |
Source PubMed
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| KDR | 3791 | PubTator's text mining | https://conductscience.org/library/genes/3791 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41375124
GET https://conductscience.org/api/papers/v1/41375124/references?page=2